LINES: Eurosarc Trial of Linsitinib in Advanced Ewing Sarcoma

• Sponsor: University of Oxford (Other)
• Overall Status: Completed
• CT.gov ID: NCT02546544
• Collaborator: European Organisation for Research and Treatment of Cancer - EORTC (Other), European Commission (Other), Astellas Pharma Inc (Industry), Oxford University Hospitals NHS Trust (Other)
• Enrollment: 16
• Locations: 5
• Arm: 1
• Duration (Months): 28.5
• Patients Per Site: 3.2
• Patients Per Site Per Month: 0.1

Study Details

Study Description

Brief Summary

This is an international, multi-centre, single arm Bayesian designed phase 2 study to identify and determine the safety and activity of anti-IGF-1/IR inhibition in patients with relapsed and/or refractory ESFT. Approximately 40 patients will be recruited from 5-7 European centres. Each patient will be treated with single agent linsitinib, 600 mg orally once a day for days 1-3, 8-10 and 15-17 on a 21 day cycle until disease progression or undue toxicity.

Condition or Disease	Intervention/Treatment	Phase
Relapsed Ewing Sarcoma; Refractory Ewing Sarcoma	Drug: Linsitinib	Phase 2

Detailed Description

An important development in ES has been the identification of IGF-1R pathway dependency. The reasons for the remarkable single agent efficacy observed in a small subset of patients remains unknown, as is the relative lack of efficacy in the majority of patients. There may be heterogeneity in response due to partial signal pathway inhibition at the tumour level, inherent resistance in ES cells or the presence of alternative pathway activation through IR-A receptor signalling.

Here we aim to establish pharmacodynamic responses in ES tumours using functional imaging 18FDG-PET-CT and repeat post treatment biopsy for biomarker responses, toxicity and clinical outcome to the dual anti-IGF-1R/IR kinase blocking single agent linsitinib.

This is a single arm phase 2 study utilising adaptive Bayesian analysis. Approximately 40 patients will be recruited the national bone sarcoma centre in 5 EU countries over 18 months.

Eligible patients will take 4x 150 mg tablets once a day, days 1-3 of the week followed by 4 days off - repeated for 3 weeks = one treatment cycle. Patients can remain on treatment for as long as they gain clinical benefit.

The primary objectives are to determine the effect of linsitinib on the patient's tumours in terms of changes in biomarker and PET scans and to establish the safety of the trial drug (linsitinib) in Ewing sarcoma at the dose and treatment schedule being used in the trial.

Study Design

• Study Type: Interventional
• Actual Enrollment: 16 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Phase II Trial of Linsitinib (Anti-IGF-1R/IR) in Patients With Relapsed and/or Refractory Ewing Sarcoma
• Study Start Date: Mar 1, 2014
• Actual Primary Completion Date: Jul 15, 2016
• Actual Study Completion Date: Jul 15, 2016

Arms and Interventions

Arm	Intervention/Treatment
Other: Linsitinib Linsitinib is to be taken orally once a day on days 1-3, 8-10 and 15-17 on a 21 day cycle. The starting dose is 600 mg	Drug: Linsitinib; Other Names: OSI-906 ASP7487

Outcome Measures

Primary Outcome Measures

1. Number of Participants With a Metabolic Response as Evaluated by PERCIST v1.0 [Pre- and Post- dose responses following 1 cycle (21 days) of treatment]

   Metabolic response measured by PERCIST v1.0 using SULpeak. This methodology used SULpeak to measure change in glucose uptake in the tumour. Complete Metabolic Response - Complete resolution of 18F-FDG uptake within measurable target lesion so that it is less than mean liver activity and indistinguishable from surrounding background blood-pool levels. Partial Metabolic Response - Reduction of minimum of 30% in target measurable tumour 18F-FDG SULpeak. Absolute drop in SUL must be at least 0.8 SUL units, as well. No new lesions. Positive Metabolic Response - Participants having either "Complete Metabolic Response" or "Partial Metabolic Response". Stable Metabolic Disease - Not CMR, PMR or PMD. Progressive metabolic disease - Increase of more than 30% in 18F-FDG SUL peak. OR: Visible increase in extent of 18F-FDG tumour uptake (75% in TLG volume with no decline in SUL. OR: New 18F-FDG-avid lesions that are typical of cancer and not related to treatment effect or infection.

2. Number of Participants With a Toxic Event [Following 6 cycles of treatment (up to 6 months)]

   A patient is defined as having a toxic event if they experienced at least one grade 3 adverse event (CTCAE v4.0 grade)

Secondary Outcome Measures

1. Clinical Outcome (PFS, DSS) [Duration of study (up to 18 months)]

   To determine the clinical outcome through assessment of Progression free survival; where length of survival is defined in whole days as the time from entry into the study until Ewing sarcoma progression or death from any cause. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Disease specific survival; where length of survival is defined in whole days as the time from entry into the study until death from Ewing sarcoma.

2. Pharmacokinetics Assays of Following Linsitinib Treatment (Plasma Concentrations of Linsitinib) [Cycle 1 days 1,15,17, Cycle 2 day 3, Cycle 3 days 1 and 3, Cycle 4 day 1, Cycle 5 day 1, Cycle 6 day 1 and End of Treatment.0]

   Plasma concentrations of linsitinib (ng/ml). Samples were taken 3 hours post-dose at Cycle 1 days 1,15,17, Cycle 2 day 3, Cycle 3 days 1 and 3, Cycle 4 day 1, Cycle 5 day 1, Cycle 6 day 1, and End of Treatment (this could occur at anytime during the 6 cycles).

3. Number of Participants With a Radiological Response as Evaluated by RECIST v1.1 [Measured cycle 1 day 15, cycle 3 and cycle 6]

   Radiological response measured using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) Per RECIST for target lesions and assessed by CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Progressive Disease (PD), >20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; Stable disease (SD), Not CR, PR or PD.

4. Number of Participants With a Metabolic Response as Evaluated by EORTC 1.0 [Measured cycle 1 day 15]

   Metabolic response measured by PERCIST v1.0 using SULpeak. This methodology used SULpeak to measure change in glucose uptake in the tumour. Complete Metabolic Response - Complete resolution of 18F-FDG uptake within measurable target lesion so that it is less than mean liver activity and indistinguishable from surrounding background blood-pool levels. Partial Metabolic Response - Reduction of minimum of 30% in target measurable tumour 18F-FDG SULpeak. Absolute drop in SUL must be at least 0.8 SUL units, as well. No new lesions. Positive Metabolic Response - Participants having either "Complete Metabolic Response" or "Partial Metabolic Response". Stable Metabolic Disease - Not CMR, PMR or PMD. Progressive metabolic disease - Increase of more than 30% in 18F-FDG SUL peak. OR: Visible increase in extent of 18F-FDG tumour uptake (75% in TLG volume with no decline in SUL. OR: New 18F-FDG-avid lesions that are typical of cancer and not related to treatment effect or infection.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 70 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Histological or cytological confirmed original (no new biopsy required) diagnosis of Ewing sarcoma, preferably with EWSR in situ hybridisation break apart probe.

• First, second or any relapse or refractory disease to conventional treatment

• Current disease state for which there either is no known curative therapy or therapy proven to prolong survival with an acceptable quality of life

• Has recovered from prior chemotherapy-related toxicity to ≤ grade 2

• Male or female, Age ≥ 18 and ≤70 years

• Life expectancy of at least 4 months

• WHO performance score of 0-2

• Must be able to take oral medication

• Is willing and able to comply with the protocol for the duration of the study, and scheduled visits and examinations, including biopsies and PET-CT scans

• Written (signed and dated) informed consent

• Tumour at biopsy accessible site; in the case of lung metastases, accessible with VATS procedure

• Tumour progression documented with imaging in the 6 months prior to study entry

• At least one measurable lesion on CT scan performed in past 14 days of minimum size 1 cm and 18FDG uptake positive

• Cardiac Ejection Fraction (Echocardiogram) ≥45%

• Fasting glucose ≤ 150 mg/dL (8.3 mmol/L) with no history of diabetes. Concurrent use of non-insulinotropic anti-hyperglycaemic therapy for diabetes is permitted if the dose has been stable for ≥ 4 weeks at the time of enrolment

• 1. Haematological and biochemical indices within the specified ranges as below:

• Haemoglobin (Hb) ≥9 g/dL (Previous transfusion is allowed)

• Absolute neutrophil count (ANC) ≥1.0 x 109/L without growth factor support

• Platelet count > 80.x 109/L (Previous transfusion is allowed)

• Direct Bilirubin <1.5 times the upper limit of normal (ULN)

• Serum alanine aminotransferase (ALT) <2.5 x ULN for age and ≤ 5 x ULN if liver metastasis

• Aspartate aminotransferase (AST) <2.5 x ULN for age

• Alkaline phosphatase <2.5 x ULN for age

• CPK <2.5 x ULN for age

• Serum creatinine ≤1.5 x ULN for age

• Potassium, magnesium and calcium within normal limits (supplementation and re-testing is permitted)

Exclusion Criteria:

• Females: Pregnant or breast-feeding, or of childbearing potential unless effective methods of contraception are used. Males: Unless effective methods of contraception are used.

• Significant active cardiac disease including: History (within last 6 months) of significant cardiovascular disease unless the disease is well-controlled. Significant cardiac disease includes second/third degree heart block; clinically significant ischemic heart disease; superior vena cava (SVC) syndrome; poorly controlled hypertension; congestive heart failure of New York Heart Association (NYHA) Class II or worse (slight limitation of physical activity; comfortable at rest, but ordinary physical activity results in fatigue, palpitation, or dyspnea).

• History of arrhythmia (multifocal premature ventricular contractions [PVCs], bigeminy, trigeminy, ventricular tachycardia, or uncontrolled atrial fibrillation) that is symptomatic or requires treatment (≥ grade 3), left bundle branch block (LBBB), or asymptomatic sustained ventricular tachycardia are not allowed. Patients with atrial fibrillation controlled by medication are not excluded; uncontrolled high blood pressure (no greater than 2 SD above the mean for age for SBP and DBP), unstable angina, congestive heart failure, myocardial infarction within the previous 6 months, or serious cardiac arrhythmias

• Mean QTcF interval ≥ 450 msec based on analysis of screening visit and pre-dose ECGs.

• 1. Use of drugs that have a known risk of causing Torsades de Pointes (TdP) within 14 days prior to registration

• Use of the potent CYP1A2 inhibitors ciprofloxacin and fluvoxamine within 7 days prior to registration. Linsitinib is primarily metabolized by CYP1A2 and inhibitors/inducers of CYP1A2 could alter the pharmacokinetics of linsitinib. Other less potent CYP1A2 inhibitors/inducers are not excluded

• Other psychological, social or medical condition, physical examination finding or a laboratory abnormality that the Investigator considers would make the patient a poor trial candidate or could interfere with protocol compliance or the interpretation of trial results

• Any other active malignancy, with the exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri and non-melanoma skin lesions

• History of cerebrovascular accident (CVA) within 6 months prior to entry that resulted in ongoing neurologic instability

• Patients with symptomatic brain metastases. Patients with previously diagnosed brain metastases are eligible if they have completed their CNS treatment and have recovered from the acute effects of radiation therapy or surgery prior to the start of study medication, have discontinued corticosteroid treatment for these metastases for at least 4 weeks, and are neurologically stable

• Major surgery within 4 weeks prior to study treatment

• Prior anti- IGF-1R treatment

• Treatment with any other investigational agent, or participation in another clinical trial within 28 days prior to enrolment

• Patients who are known to be serologically positive for Hepatitis B, Hepatitis C or HIV

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Universitè Lyon 1 Claude Bernard	Lyon		France
2	Pediatric Hematology and Oncology, University Hospital Münster	Münster		Germany	48149
3	Istituti Ortopedici Rizzoli	Bologna		Italy	40136
4	Department of Clinical Oncology, Leiden University Medical Center	Leiden	Postzone K1-P	Netherlands	P.O. Box 9600
5	Oxford University Hospitals NHS Foundation Trust	Oxford		United Kingdom	OX3 7LE

Sponsors and Collaborators

• University of Oxford
• European Organisation for Research and Treatment of Cancer - EORTC
• European Commission
• Astellas Pharma Inc
• Oxford University Hospitals NHS Trust

Investigators

• Principal Investigator: Andrew B Hassan, BMBCh FRCP, University of Oxford

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

• ISRCTN registry

Publications

None provided.

• Responsible Party: University of Oxford
• ClinicalTrials.gov Identifier: NCT02546544
• Other Study ID Numbers: OCTO_038; 2012-000616-28
• First Posted: Sep 11, 2015
• Last Update Posted: Jun 3, 2019
• Last Verified: Oct 1, 2017

• Keywords provided by University of Oxford: Linsitinib; anti-IGF-1R/IR; Ewing Sarcoma; dual IGF-1R/IR inhibition; Relapsed Ewing Sarcoma; Refractory Ewing Sarcoma; Metastatic Ewing Sarcoma
• Additional relevant MeSH terms: Sarcoma; Sarcoma, Ewing

Study Results

Participant Flow

Recruitment Details	Patients were recruited from March 2014 until April 2016 at specialist cancer hospitals across Europe

Arm/Group Title	Linsitinib
Arm/Group Description	Linsitinib is to be taken orally once a day on days 1-3, 8-10 and 15-17 on a 21 day cycle. The starting dose is 600 mg
Period Title: Overall Study
STARTED	16
Received Allocated Intervention	16
COMPLETED	0
NOT COMPLETED	16

Baseline Characteristics

Arm/Group Title	Linsitinib
Arm/Group Description	Linsitinib is to be taken orally once a day on days 1-3, 8-10 and 15-17 on a 21 day cycle. The starting dose is 600 mg
Overall Participants	16
Age (years) [Median (Inter-Quartile Range) ]
Median (Inter-Quartile Range) [years]	26.3
Sex: Female, Male (Count of Participants)
Female	3 18.8%
Male	13 81.3%
Region of Enrollment (participants) [Number]
Netherlands	2 12.5%
United Kingdom	8 50%
Italy	4 25%
Germany	2 12.5%
WHO performance status (Count of Participants)
0	5 31.3%
1	7 43.8%
2	4 25%
Histology - Ewing Sarcoma (Count of Participants)
Count of Participants [Participants]	16 100%
Primary site (Count of Participants)
Chest wall	4 25%
Extra-osseous site	2 12.5%
Lower extremity	3 18.8%
Pelvis	5 31.3%
Spine	1 6.3%
Upper extremity	1 6.3%
Disease stage at screening - Metastatic (Count of Participants)
Count of Participants [Participants]	16 100%
Sites of metastases (participants) [Number]
Bone	3 18.8%
Lung	11 68.8%
Bone, Other	8 50%
Number of lines of previous treatment (Count of Participants)
Second line	1 6.3%
Third line	1 6.3%
> third line	14 87.5%
Time since most recent relapse/progression (days) (days) [Median (Inter-Quartile Range) ]
Median (Inter-Quartile Range) [days]	18
Prior radiotherapy (Count of Participants)
Count of Participants [Participants]	13 81.3%
Prior chemotherapy (Count of Participants)
Count of Participants [Participants]	16 100%
Prior surgery (Count of Participants)
Count of Participants [Participants]	14 87.5%

Outcome Measures

1. Primary Outcome

Title	Number of Participants With a Metabolic Response as Evaluated by PERCIST v1.0
Description	Metabolic response measured by PERCIST v1.0 using SULpeak. This methodology used SULpeak to measure change in glucose uptake in the tumour. Complete Metabolic Response - Complete resolution of 18F-FDG uptake within measurable target lesion so that it is less than mean liver activity and indistinguishable from surrounding background blood-pool levels. Partial Metabolic Response - Reduction of minimum of 30% in target measurable tumour 18F-FDG SULpeak. Absolute drop in SUL must be at least 0.8 SUL units, as well. No new lesions. Positive Metabolic Response - Participants having either "Complete Metabolic Response" or "Partial Metabolic Response". Stable Metabolic Disease - Not CMR, PMR or PMD. Progressive metabolic disease - Increase of more than 30% in 18F-FDG SUL peak. OR: Visible increase in extent of 18F-FDG tumour uptake (75% in TLG volume with no decline in SUL. OR: New 18F-FDG-avid lesions that are typical of cancer and not related to treatment effect or infection.
Time Frame	Pre- and Post- dose responses following 1 cycle (21 days) of treatment

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Linsitinib
Arm/Group Description	Linsitinib is to be taken orally once a day on days 1-3, 8-10 and 15-17 on a 21 day cycle. The starting dose is 600 mg
Measure Participants	16
Positive metabolic response	1 6.3%
Stable metabolic disease	2 12.5%
Progressive metabolic disease	4 25%
Not measurable at Baseline	3 18.8%
Not assessable - liver	4 25%
No repeat scan available	2 12.5%

2. Primary Outcome

Title	Number of Participants With a Toxic Event
Description	A patient is defined as having a toxic event if they experienced at least one grade 3 adverse event (CTCAE v4.0 grade)
Time Frame	Following 6 cycles of treatment (up to 6 months)

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Linsitinib
Arm/Group Description	Linsitinib is to be taken orally once a day on days 1-3, 8-10 and 15-17 on a 21 day cycle. The starting dose is 600 mg
Measure Participants	16
Experienced a toxic event	5 31.3%
Did not experienced a toxic event	11 68.8%

3. Secondary Outcome

Title	Clinical Outcome (PFS, DSS)
Description	To determine the clinical outcome through assessment of Progression free survival; where length of survival is defined in whole days as the time from entry into the study until Ewing sarcoma progression or death from any cause. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Disease specific survival; where length of survival is defined in whole days as the time from entry into the study until death from Ewing sarcoma.
Time Frame	Duration of study (up to 18 months)

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Linsitinib
Arm/Group Description	Linsitinib is to be taken orally once a day on days 1-3, 8-10 and 15-17 on a 21 day cycle. The starting dose is 600 mg
Measure Participants	16
Disease specific survival	7.1
Progression free survival	1.3

4. Secondary Outcome

Title	Pharmacokinetics Assays of Following Linsitinib Treatment (Plasma Concentrations of Linsitinib)
Description	Plasma concentrations of linsitinib (ng/ml). Samples were taken 3 hours post-dose at Cycle 1 days 1,15,17, Cycle 2 day 3, Cycle 3 days 1 and 3, Cycle 4 day 1, Cycle 5 day 1, Cycle 6 day 1, and End of Treatment (this could occur at anytime during the 6 cycles).
Time Frame	Cycle 1 days 1,15,17, Cycle 2 day 3, Cycle 3 days 1 and 3, Cycle 4 day 1, Cycle 5 day 1, Cycle 6 day 1 and End of Treatment.0

Outcome Measure Data

Analysis Population Description

Data provided is as collected.

Arm/Group Title	Linsitinib
Arm/Group Description	Linsitinib is to be taken orally once a day on days 1-3, 8-10 and 15-17 on a 21 day cycle. The starting dose is 600 mg
Measure Participants	16
Screening	1
Cycle 1 Day 1	4790
Cycle 1 Day 15	2163
Cycle 1 Day 17	4977
Cycle 2 Day 3	3409
Cycle 3 Day 1	6791
Cycle 3 Day 3	1964
Cycle 4 Day 1	3591
End of treatment visit	1

5. Secondary Outcome

Title	Number of Participants With a Radiological Response as Evaluated by RECIST v1.1
Description	Radiological response measured using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) Per RECIST for target lesions and assessed by CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Progressive Disease (PD), >20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; Stable disease (SD), Not CR, PR or PD.
Time Frame	Measured cycle 1 day 15, cycle 3 and cycle 6

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Linsitinib
Arm/Group Description	Linsitinib is to be taken orally once a day on days 1-3, 8-10 and 15-17 on a 21 day cycle. The starting dose is 600 mg
Measure Participants	16
Stable disease	7 43.8%
Progressive disease	7 43.8%
No repeat scan available	2 12.5%
Stable disease	2 12.5%
Progressive disease	4 25%
No repeat scan available	10 62.5%
Stable disease	0 0%
Progressive disease	0 0%
No repeat scan available	16 100%

6. Secondary Outcome

Title	Number of Participants With a Metabolic Response as Evaluated by EORTC 1.0
Description	Metabolic response measured by PERCIST v1.0 using SULpeak. This methodology used SULpeak to measure change in glucose uptake in the tumour. Complete Metabolic Response - Complete resolution of 18F-FDG uptake within measurable target lesion so that it is less than mean liver activity and indistinguishable from surrounding background blood-pool levels. Partial Metabolic Response - Reduction of minimum of 30% in target measurable tumour 18F-FDG SULpeak. Absolute drop in SUL must be at least 0.8 SUL units, as well. No new lesions. Positive Metabolic Response - Participants having either "Complete Metabolic Response" or "Partial Metabolic Response". Stable Metabolic Disease - Not CMR, PMR or PMD. Progressive metabolic disease - Increase of more than 30% in 18F-FDG SUL peak. OR: Visible increase in extent of 18F-FDG tumour uptake (75% in TLG volume with no decline in SUL. OR: New 18F-FDG-avid lesions that are typical of cancer and not related to treatment effect or infection.
Time Frame	Measured cycle 1 day 15

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Linsitinib
Arm/Group Description	Linsitinib is to be taken orally once a day on days 1-3, 8-10 and 15-17 on a 21 day cycle. The starting dose is 600 mg
Measure Participants	16
Positive metabolic response	2 12.5%
Stable metabolic disease	5 31.3%
Progressive metabolic disease	7 43.8%
No repeat scan available	2 12.5%

Adverse Events

Time Frame	Adverse events were collected from baseline until 28 days post treatment.
Arm/Group Title	Linsitinib
Arm/Group Description	Linsitinib is to be taken orally once a day on days 1-3, 8-10 and 15-17 on a 21 day cycle. The starting dose is 600 mg
All Cause Mortality
	Linsitinib
	Affected / at Risk (%)	# Events
Total	13/16 (81.3%)
Serious Adverse Events
	Linsitinib
	Affected / at Risk (%)	# Events
Total	3/16 (18.8%)
Gastrointestinal disorders
Diarrhoea	1/16 (6.3%)
Respiratory, thoracic and mediastinal disorders
Pneumothorax	1/16 (6.3%)
Pneumonia	1/16 (6.3%)
Other (Not Including Serious) Adverse Events
	Linsitinib
	Affected / at Risk (%)	# Events
Total	15/16 (93.8%)
Blood and lymphatic system disorders
Anaemia	1/16 (6.3%)
Thrombocytopenia	1/16 (6.3%)
Gastrointestinal disorders
Abdominal discomfort	1/16 (6.3%)
Constipation	2/16 (12.5%)
Diarrhoea	1/16 (6.3%)
Nausea	2/16 (12.5%)
Vomiting	2/16 (12.5%)
General disorders
Chest discomfort	1/16 (6.3%)
Chest pain	1/16 (6.3%)
Fatigue	4/16 (25%)
Pain	1/16 (6.3%)
Infections and infestations
Pharyngitis streptococcal	1/16 (6.3%)
Respiratory tract infection	1/16 (6.3%)
Injury, poisoning and procedural complications
Spinal cord injury	1/16 (6.3%)
Investigations
Blood creatine phosphokinase increased	1/16 (6.3%)
Electrocardiogram QT prolonged	6/16 (37.5%)
Haemoglobin decreased	1/16 (6.3%)
Lymphocyte count decreased	1/16 (6.3%)
Platelet count decreased	1/16 (6.3%)
Metabolism and nutrition disorders
Decreased appetite	3/16 (18.8%)
Hyperglycaemia	2/16 (12.5%)
Hypokalaemia	1/16 (6.3%)
Hypomagnesaemia	1/16 (6.3%)
Musculoskeletal and connective tissue disorders
Arthralgia	1/16 (6.3%)
Back pain	1/16 (6.3%)
Flank pain	1/16 (6.3%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tumour pain	2/16 (12.5%)
Nervous system disorders
Headache	2/16 (12.5%)
Somnolence	2/16 (12.5%)
Psychiatric disorders
Insomnia	1/16 (6.3%)
Renal and urinary disorders
Pollakiuria	1/16 (6.3%)
Respiratory, thoracic and mediastinal disorders
Dyspnoea	1/16 (6.3%)

Limitations/Caveats

[Not Specified]

More Information

Certain Agreements

All Principal Investigators ARE employed by the organization sponsoring the study.

There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.